Australia's CurveBeam AI climbs to over 2-month high on Chinese investment approval

Curvebeam AI

07/01/2026 02:29

** Shares of CurveBeam AI CVB.AX rise as much as 30.7% to A$0.098, their highest level since October 31

** The specialised medical imaging equipment developer set for its best day since late September, if gains hold

** Says Shandong WeiYing Intelligent Medical Technology gets formal Chinese regulatory approval required to make strategic investment in CurveBeam

** Says first tranche of investment from Shandong covers A$4 million ($2.70 million) with further A$6 million to be made available on achieving certain milestones

** About 6.2 million shares change hands, 10.5x their 30-day average volume

** Stock down 45.2% in 2025

($1 = 1.4824 Australian dollars)

 (Reporting by John Biju in Bengaluru)

 ((John.Biju@thomsonreuters.com;))